AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 GuidanceBusiness Wire • 01/05/24
AngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 12/12/23
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024Business Wire • 12/07/23
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary EmbolismBusiness Wire • 12/07/23
AngioDynamics (ANGO) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 12/05/23
AngioDynamics (ANGO) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research • 11/29/23
AngioDynamics (ANGO) Outperforms Broader Market: What You Need to KnowZacks Investment Research • 11/23/23
AngioDynamics (ANGO) Advances But Underperforms Market: Key FactsZacks Investment Research • 11/11/23
AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 GuidanceBusiness Wire • 10/04/23
AngioDynamics: Enormous Effort Required In Fiscal '24 To Reverse The Equity PictureSeeking Alpha • 09/17/23
AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023Business Wire • 09/12/23
AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart VegetationBusiness Wire • 08/15/23
AngioDynamics to Participate in a Fireside Chat at the Canaccord Genuity Growth ConferenceBusiness Wire • 07/31/23